Jefferies 2017 Global Healthcare Conference
(NASDAQ: TTOO)
June 7, 2017
Forward-Looking Statements

This presentation contains forward-looking statements. These statements reflect the current views of senior management of T2 Biosystems with respect to future events and financial performance. These statements include forward-looking statements with respect to the Company’s business and industry, as well as its strategy, future operations, prospects, plans and objectives. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities laws or otherwise. Forward-looking statements address matters that involve risks and uncertainties. The factors that could cause actual results to differ materially from those in the forward-looking statements include, among others: (i) T2 Biosystems’ status as an early commercial-stage company and its expectation to incur losses in the future; (ii) T2 Biosystems’ ability to obtain marketing authorization from the FDA or regulatory clearance for its additional product candidates in the United States or any other jurisdiction; (iii) the market acceptance of T2 Biosystems’ T2MR technology; (iv) T2 Biosystems’ ability to timely and successfully develop and commercialize its existing and future product candidates; (v) T2 Biosystems’ ability to successfully manage its growth; (vi) federal, state and foreign regulatory requirements, including FDA regulation of T2 Biosystems’ product candidates; and (vii) other risk factors included in T2 Biosystems’ annual report on form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2017 as well as its quarterly reports on form 10-Q and other documents filed by T2 Biosystems with the SEC from time to time. Accordingly, there are or will be important factors that could cause T2 Biosystems’ actual results to differ materially from those indicated in these statements. The statements made herein speak only as of the date of this presentation.

Publicly Available Documents

For additional information regarding T2 Biosystems, you should review the documents that T2 Biosystems has filed with the SEC, including its annual report on Form 10-K filed on March 15, 2017, and its future current and periodic reports to be filed with the SEC. You can obtain such documents for free by visiting EDGAR on the SEC website at www.sec.gov.

2 Liu, V. et al. Sepsis contributes to nearly half of all hospital deaths in the US. ATS 2014; Abstract A2168.
3 HCUP Statistical Brief #204. May 2016; Agency for Healthcare Research and Quality, Rockville, MD.
6 HCUP Statistical Brief #122. October 2011; Agency for Healthcare Research and Quality, Rockville, MD.
15 Premier healthcare alliance economic outlook – Fall 2012
16 Toner RW et al., Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy, 2011;9(1):23-37
The Reason We Are Here

A platform technology that fundamentally changes the way that medicine is practiced by transforming diagnostics for the tangible benefit of patients, practitioners and healthcare institutions.

- **T2MR**
  - Innovative technology with broad applications

- **Market**
  - $3B+ Initial market potential

- **Sepsis Diagnostics**
  - Provide species-specific results, direct from whole blood, in 3-5 hours\(^1\)

- **Reimbursement**
  - Products covered by existing reimbursement codes

- **Robust Pipeline**
  - A new generation of diagnostics

- **Execution**
  - High-risk patient access growing and several collaborations announced
Our Priorities

1. Continue to expand globally and gain access to patients within the customer base who are at high-risk of sepsis infection and could be tested with our sepsis diagnostic products.

2. Introduce new products to broaden current suite of solutions.

3. Highlight customer success stories to demonstrate the impact that T2MR technology is having on patient care and hospital economics.

4. Develop partnership pipeline to help accelerate growth profile.
T2MR Revolution

A platform technology with multiple, billion-dollar franchise opportunities in the U.S. alone

Current Applications

- **FDA Clearing**
  - **T2Candida**
    - 6.75M high-risk patients
  - **T2Bacteria**
    - 8.75M high-risk patients
- **T2GNR**
  - Resistance Panel for 500K+ positive patients
- **T2MR**
  - Hemostasis, Research & Companion Dx

Potential Future Applications

- **Infectious Disease**
- **Cancer**
- **Cardiac**
- **Wellness**

**Clinical Trials**

- **T2Lyme**
  - Clinical Trial targeting 2018
  - 3.4M Lyme tests run annually

**Others**

- **FDA filing targeted mid-2017**
  - 3.4M Lyme tests run annually
The Facts About Sepsis

Most expensive hospital-treated condition in the U.S.

- Contributes to nearly 1 in 2 hospital deaths\(^2\)
- Representing $23.7B in U.S. healthcare costs\(^3\)
- Claims more lives annually than breast cancer, prostate cancer and AIDS, combined\(^4\)
- More than 1 in 5 surviving patients die within 2 years as a consequence of sepsis\(^5\)
- More than 1.6M diagnosed annually in the U.S. and ~500,000 die\(^6\)
- Candida is the most lethal, common sepsis-causing pathogen\(^7,8\)
T2MR Provides Faster, More Accurate Sepsis Pathogen Detection

Time and sensitivity of blood culture alone is not enough

- **3-5 Hours**
  - T2Candida Results
  - >90% Detected

- **~5-10 Hours**
  - Patient on the right drug

**T2Candida**

- **1-5 days Blood Culture Growth**
  - > Once positive
  - > 1-48 hours: Species Identification

- **0 Hours**
  - Symptoms present
  - Blood samples taken

- **24 Hours**
  - Some blood culture positive results completed

- **120 Hours**
  - Final positive blood culture results completed
  - 60% Sensitive

- **120 Hours**
  - Negative blood culture results reported

- **~27 Hours-7 Days**
  - Patient on the right drug

Transforming Diagnostics, Patient Care & Economics | 7
T2Candida Addresses Large Unmet Market Need

6.75M high-risk patients

Only technology that can derive species-specific results directly from blood

_Candida: The Facts_

40% Mortality Rate

50% of infections are missed by blood culture

$130K Average cost per patient

40 Days in the hospital

Each hour of delayed treatment increases mortality risk nearly 8%

4th Leading hospital-acquired bloodstream infection

135,000+ Patients per year

Transforming Diagnostics, Patient Care & Economics | 8
T2Candida Panel is Changing Treatment Protocols

Growing number of T2Candida customer success stories

- Statistically powered Study demonstrating $2.3MM in annual hospital savings
- Reduced median ICU length of stay per patient by 7 days (p=0.009)
- Reduction in total length of stay by 4 days/patient (p=0.164)
- 75% of negative patients had antifungals discontinued or deescalated

**Lee Memorial Health System**

- Average length of stay per patient reduced by 7 days
- Unnecessary antifungal therapy was avoided in 41% of patients
- Unnecessary antifungal therapy was discontinued after 1 dose in another 15% of patients
- Average net antifungal savings of approximately ~$200 for every patient tested

**Huntsville Hospital**

- Reduction in duration of therapy and time to de-escalation in negative patients resulted in pharmacy savings of ~$500 per patient
- T2Candida detected 56% more positive patients than blood culture

**Riverside Community Hospital**

- 83% of patients who tested positive received appropriate therapy within 6 hours of the blood draw and 100% in under 9 hours
- 0 patients who tested positive had been on antifungals prior to testing
- Therapy was discontinued for 100% of the patients who tested negative

T2Candida Panel is detected 56% more positive patients than blood culture

- Unnecessary antifungal therapy was avoided in 41% of patients
- Unnecessary antifungal therapy was discontinued after 1 dose in another 15% of patients
- Average net antifungal savings of approximately ~$200 for every patient tested

- Average length of stay per patient reduced by 7 days
- Unnecessary antifungal therapy was avoided in 41% of patients
- Unnecessary antifungal therapy was discontinued after 1 dose in another 15% of patients
- Average net antifungal savings of approximately ~$200 for every patient tested

- Reduction in duration of therapy and time to de-escalation in negative patients resulted in pharmacy savings of ~$500 per patient
- T2Candida detected 56% more positive patients than blood culture

- 83% of patients who tested positive received appropriate therapy within 6 hours of the blood draw and 100% in under 9 hours
- 0 patients who tested positive had been on antifungals prior to testing
- Therapy was discontinued for 100% of the patients who tested negative

Transforming Diagnostics, Patient Care & Economics | 9
T2Candida Penetration and Goals

Commercial traction growing

Penetration through 2016

- Targeting Top 450 Hospitals
- 420K Estimated number of high-risk patients in hospital customer base
- 126 Hospitals with access to T2Candida

4Q16 – Q317 Target – Prior to Expected T2Bacteria Launch

- 150K Target to increase number of high-risk patients in hospital customer base
- 130K Progress as of March 31, 2017
T2Bacteria Panel

Along with the T2Candida Panel will be run on the T2Dx Instrument

- Will leverage T2Candida installed customer base, designed to identify the species of bacterial infections in 3-6 hours
- The T2Bacteria pivotal study will take place in 10 U.S. hospitals and test a minimum of 1,850 patient samples
- FDA Clinical Trial results and FDA filing are anticipated by mid-2017

Transforming Diagnostics, Patient Care & Economics
**Potential T2Bacteria Impact Based on Published Data**

**T2Bacteria Expected Length of Stay Reductions with Appropriate Rx in 1st 24 hours**

<table>
<thead>
<tr>
<th></th>
<th><em>E. faecium</em>&lt;sup&gt;1&lt;/sup&gt;</th>
<th><em>S. aureus</em>&lt;sup&gt;2&lt;/sup&gt;</th>
<th><em>K. pneumoniae</em>&lt;sup&gt;3&lt;/sup&gt;</th>
<th><em>A. baumannii</em>&lt;sup&gt;4&lt;/sup&gt;</th>
<th><em>P. aeruginosa</em>&lt;sup&gt;5&lt;/sup&gt;</th>
<th><em>E. coli</em>&lt;sup&gt;6&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICU (days)</strong></td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td><strong>Hospital (days)</strong></td>
<td>7</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>

**Length of Stay Reduction with Appropriate Rx in 1st 24 hours**

<table>
<thead>
<tr>
<th></th>
<th>ICU (days)</th>
<th>Hospital (days)</th>
<th>Cost per ICU Day&lt;sup&gt;7&lt;/sup&gt;</th>
<th>Cost per Hospital Day&lt;sup&gt;7&lt;/sup&gt;</th>
<th>Total Length of Stay savings per positive patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3</td>
<td>7</td>
<td>$4,150</td>
<td>$1,560</td>
<td>$23,400</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>3</td>
<td></td>
<td></td>
<td>$25,400</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
<td>$22,800</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>1</td>
<td></td>
<td></td>
<td>$29,100</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>6</td>
<td></td>
<td></td>
<td>$38,400</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
<td>$22,800</td>
</tr>
</tbody>
</table>

Combination of T2Candida and T2Bacteria may enable 95% of sepsis patients to receive rapid and appropriate therapy AND will expand our target market to top ~2,500 hospitals in the U.S.
Transforming Diagnostics, Patient Care & Economics

A platform technology with multiple, billion-dollar franchise opportunities

**T2MR**
- Innovative technology with broad applications

**Market**
- $3B+ Initial market potential

**Sepsis Diagnostics**
- Provide species-specific results, direct from whole blood, in 3-5 hours\(^1\)

**Reimbursement**
- Products covered by existing reimbursement codes

**Robust Pipeline**
- A new generation of diagnostics

**Execution**
- High-risk patient access growing and several collaborations announced